Source: Annual Congress 2001 - Problems in treatment of TB
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. A. Torossian, A. Garova, G. Belev, V. Hodgev, S. Kartev, P. Mandulova (Plovdiv, Bulgaria). Therapeutical problems related to drug-resistance in terms of DOTS. Eur Respir J 2001; 16: Suppl. 31, 2077

Member's Comments

No comment yet.

Related content which might interest you: Impact of drug resistance among new cases on outcome of DOTS category I Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Particular aspects of TB endemia in Bucharest after adoption DOTS strategy Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 Improved treatment outcome of MDR-TB in Eastern Taiwan: Reducing default rate by DOTS Plus Source: Annual Congress 2013 –Tuberculosis: clinical epidemiology and public health Year: 2013 Drug resistance in previously treated patients of tuberculosis in pre DOTS and DOTS era and its implications Source: Annual Congress 2009 - Tuberculosis control Year: 2009 Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Poor treatment outcomes of XDR-TB patients in resource-limited settings Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021 Two major problems in TB patients today: MDR and the abandoned therapy Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 How does primary health care providers‘ pre-knowledge on tuberculosis affect the implementation of DOTS strategy in Serbia? Source: Eur Respir J 2006; 28: Suppl. 50, 19s Year: 2006 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Impact of applying the DOTS strategy on the TB endemic evolution in Bucharest Source: Eur Respir J 2007; 30: Suppl. 51, 422s Year: 2007 Outcomes of DOTS and DOTS Plus regimens implementing among patients with pulmonary tuberculosis relapses Source: Eur Respir J 2002; 20: Suppl. 38, 369s Year: 2002 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009